



Clarivate szerepe az innovációs ciklusban

Tóth Szász Enikő


2022. január 24.



Emberi találékonyság és innováció az összetett kihívások megoldására

A megbízható tartalomhoz való hozzáféréssel, fejlett adattudományi képességeinkkel és az innováció teljes életciklusára kiterjedő mély szakértelemmel segítjük az ügyfeleinket az innováció előmozdításában és védelmében.

<https://clarivate.com/>



Az innováció életciklusa



Felfedezés

Lehetőségek megállapítása

Kereskedelmi forgalom

Gyorsabb piacra vitel,
márka erősítése

Védelem

Megfelelő kockázatok
felvállalása

Clarivate teljes portfóliója

IP Division

 Clarivate
Web of Science™

 Clarivate
Cortellis™

DRG
Part of Clarivate

 Clarivate
Derwent™

 Clarivate
MarkMonitor™

CPA GLOBAL
Part of Clarivate

Science Division



Our mission

We are a trusted, indispensable partner to innovators everywhere delivering critical data, information, workflow solutions and deep domain expertise.



Our purpose

We believe human ingenuity can transform the world and improve our future.



Our vision

We will improve the way the world creates, protects and advances innovation.

Clarivate & ProQuest

Complementary Assets Create Industry's Most Robust, End-to-End Platform Serving the Complete Research Ecosystem



Combined assets

<p>ProQuest</p> <ul style="list-style-type: none"> ProQuest ONE ProQuest Ebook Central Academic Video Online Rialto Leganto 	<ul style="list-style-type: none"> Primo Alma Summon pivot Vega Dialog STEM Database ProQuest TDM Studio 	<ul style="list-style-type: none"> Esploro PP
<p>Clarivate</p>	<ul style="list-style-type: none"> Web of Science™ Research Assistant EndNote™ Cortellis™ Consultancy 	<ul style="list-style-type: none"> ScholarOne InCites Converis Journal Citation Reports Healthcare Data Solutions Derwent™ CompuMark™ CPA GLOBAL

5+ million dissertations

285+ million journal articles

824+ million issues of newspapers

1.8+ million e-books

7+ billion digital pages

1.9+ billion Citations

2+ million molecular interactions

32+ billion patient claims & EHR records

100+ million patent documents

Clarivate & ProQuest – not only products



~8,500

Colleagues

Our Connected Workplace strategy enables us to build inspired and highly collaborative teams across multiple global locations

- Proud heritage
- Customer-first focus
- Commitment to excellence and innovation
- Dedication to colleague engagement



~2,700

Colleagues


43 Global Offices and Knowledge in 158 Countries

Agenda

1. Clarivate`s End-to-End full suite for innovation support
2. Innovation life cycle on selected example (Kyprolis)
3. Research and Discovery phase
4. Market Assessment phase
5. Clinical Testing Phase
6. Apendix

Our premier suite of intelligence solutions

Data-driven insights spanning the entire innovation & product lifecycle






Reduce Researcher Overload

Improve the researcher experience with the best data and tools

- **1.7B** cited scholarly references
- **2.6M** molecular interactions
- **34K** academic journals
- **450K** clinical trials
- **32B** unique patient claims and HER record
- **3M** pharmacology records
- **1.9K** US hospitals' medical device purchase volume data
- **200** global disease and market forecasts
- **245K** regulatory reference documents
- **100%** of US population in enrollment data by coverage type
- **3K** patient segments covered in epidemiology studies
- **80K** pipeline programs
- **80** medical device market overviews
- **270K** variant disease associations
- **19K** US and EU hospitals' diagnosis and procedure data
- **620K** searchable chemistry compounds



High quality research produces greater funding opportunities for your institution

Web of Science solutions

We support you at every stage of your research journey

- Research discovery and workflow Solutions
- Research analytics, evaluation & management Solutions
- Research publishing solutions

Web of Science

Discover the latest research and how it fits into the world's network of ideas, people, funders and institutions with a publisher-neutral citation index trusted by leading research institutions around the world for decades.

Publons

Get your research and scholarly contributions noticed by publishers, peers, and the world at large, or learn to peer review.

EndNote

Save time authoring papers, even when you're collaborating with a large team.

Essential Science Indicators

Identify emerging science trends as well as influential individuals, institutions, papers, journals, and countries across 22 categories of research.

EndNote Click


Quickly access millions of high-quality research papers with a single mouse click.

InCites Benchmarking & Analytics

Benchmark your institution's research output against peers worldwide, identify collaborators and assess your departments and faculty with field weighted citation metrics.

Journal Citation Reports



Make confident decisions about where to submit your manuscript with the world's most influential and trusted resource for evaluating peer-reviewed journals.



Cortellis solutions

Unique suite of health and life sciences analytics solutions

- A source of comprehensive, validated, selected, regularly updated data and analysis on literature, biological pathways, protocols, facilities, patient populations and global regulatory requirements
- Cortellis delivers insights from hidden data, accelerates innovation, supports clinical trial planning and increases the odds of clinical success





[More information →](#)

Innovation life cycle on selected example Kyprolis

Following Kyprolis as an example of an asset's journey

From discovery through in-market for its first indication, Multiple Myeloma



PHASE 1 RESEARCH, DISCOVERY AND PRECLINICAL

Web of Science

The most trusted literature and citation database

- Detect breakthrough science & emerging trends
- Identify novel technologies
- Serve an unmet need
- Pinpoint the top researchers & institutions
- Examine the research funders and collaborators
- Tap into international & emerging markets

Advance your discovery efforts by uncovering emerging scientific trends earlier and faster.

EPOXOMICIN, A NEW ANTITUMOR AGENT OF MICROBIAL ORIGIN

By: HANADA, M (HANADA, M); SUGAWARA, K (SUGAWARA, K); KANETA, K (KANETA, K); TODA, S (TODA, S); NISHIYAMA, Y (NISHIYAMA, Y); TOMITA, K (TOMITA, K); YAMAMOTO, H (YAMAMOTO, H); KONISHI, M (KONISHI, M); OKI, T (OKI, T)

JOURNAL OF ANTIBIOTICS
Volume: 45 Issue: 11 Pages: 1746-1752
DOI: 10.7164/antibiotics.45.1746
Published: NOV 1992
Document Type: Article

Abstract
An actinomycete strain No. Q996-17 produced a novel compound, **epoxomicin**, which exhibited in vivo **antitumor** activity against B16 melanoma. Structural studies indicated that it is a new member of the epoxy-beta-aminoketone group, and is closely related to eponeymycin.

Keywords
Keywords Plus: BIOLOGICAL-ACTIVITY; MELANOMA

Author Information
Corresponding Address: HANADA, M (corresponding author)
BRISTOL MYERS SQUIBB, RES INST, 2-9-3 SHIMOMEGURO, MEGURO KU, TOKYO 153, JAPAN

Categories/Classification
Research Areas: Biotechnology & Applied Microbiology; Immunology; Microbiology; Pharmacology & Pharmacy

Journal information
Journal Of Antibiotics
ISSN: 0021-8820
Current Publisher: NATURE PUBLISHING GROUP, MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
Impact factor: Journal Citation Report
Research Areas: Biotechnology & Applied Microbiology; Immunology; Microbiology; Pharmacology & Pharmacy
Web of Science Categories: Biotechnology & Applied Microbiology; Immunology; Microbiology; Pharmacology & Pharmacy

Citation Network
0/160 ADD TO MARKED LIST EXPORT
Citations: highest first 1 of 4

160
Citations
All Citations
163 In All Databases
Cited References
4
View Related Records
Most Recently Cited by
Hubbell, GE; Tepe, JJ;
Natural product scaffold

2.668
Journal impact factor (2019)

1 Irreversible inhibitors of serine, cysteine, and threonine proteases 778 Citations
Powers, JC; Aspin, JL; James, KE
Dec 2002 | Chemical Reviews 764 References
Related records

2 Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity 746 Citations
Menge, LH; Mohan, B; Crews, CM
Aug 31 1999 | Proceedings Of The National Academy Of Sciences Of The United States Of America 43 References
Related records
The proteasome regulates cellular processes as diverse as cell cycle progression and NF-KB activation. In this study, we show that the potent antitumor natural product epoxomicin specifically targets the proteasome. Utilizing biotinylated-epoxomicin as a molecular probe, we demonstrate that epoxomicin covalently binds to the LMPT7, X, MECL1, and Z ca ... Show more
Free Full Text From Publisher ***

3 Potent activators of the proteasome against proteasome inhibitors 746 Citations
Kuhn, DJ; Chen, Y
Nov 1 2007 | Biochemistry 43 References
The proteasome is a major target for cancer therapy. However, the reversible proteasome inhibitors currently in clinical use do not respond to ... Show more
Free Full Text From Publisher ***

Author Information
Corresponding Address: Crews, CM (corresponding author)
Yale Univ, Dept Mol Cellular & Dev Biol, 219 Prospect St, New Haven, CT 06520 USA
E-mail Addresses: craig.crews@yale.edu
Categories/Classification
Research Areas: Science & Technology - Other Topics
Funding
Funding agency Show details Grant number
United States Department of Health & Human Services R01CA074967
National Institutes of Health NIH National Cancer Institute R01 CA074967-03
United States Department of Health & Human Services NIH National Cancer Institute CAT4967

12 Crews CM
8 Kim KB
6 Florea BI
5 Bennett MK
7 Groll M
9 Overkleeft HS
7 Van Der Marel GA
5 Orlowski RZ
5 Tsukamoto S



Create An Article Search
Search Field Type: Topic
Field Query: Robotics
Modifier: OR Search Field Type: Topic
Field Query: Engineering
ADD ROW
CREATE A SEARCH

RESEARCH & DISCOVERY
PRECLINICAL
CLINICAL
APPROVAL & LAUNCH
COMMERCIALIZATION

InCites

A customized, citation-based research analytics tool

- Visualize the most impactful researchers & organizations
- Analyze institutional or competitor productivity
- Monitor collaborations
- Investigate competitors' research funding




Organization Name	Web of Science Documents	Times Cited	Category Normalized Citation Impact	Rank
<input type="checkbox"/> Yale University	13	1,691	2.37	1
<input type="checkbox"/> Georgia Institute of Technology	1	768	3.97	2
<input type="checkbox"/> University System of Georgia	1	768	3.97	2
<input type="checkbox"/> University of North Carolina	3	714	4.92	3
<input type="checkbox"/> University of North Carolina Chapel Hill	2	684	6.56	4

Person Name	Affiliation	Rank	Web of Science Documents	Times Cited	Category Normalized Citation Impact
<input type="checkbox"/> Crews, Craig M.	Yale University	1	4	210	0.91
<input type="checkbox"/> Buckley, Dennis L.	Yale University	2	1	91	0.74
<input type="checkbox"/> Schneekloth, John S., Jr.	Yale University	3	1	16	0.37
<input type="checkbox"/> Hines, J	Yale University	4	1	3	0.17
<input type="checkbox"/> Crews, C. M.	Yale University	5	1	1	0.42

Fast-track and fund your most promising researchers and the breakthrough science in your area.

Article Title	Authors	Source	Research Area	Document Type	Volume	Issue	Pages	Publication Date	Times Cited	Journal Expected Citations	Category Expected Citations	Journal Normalized Citation Impact	Category Normalized Citation Impact	Percentile in Subject Area
Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity	Meng, LH; Mohan, R; Kwok, BH; Blafson, M; Sin, N; et al.	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA	BIOCHEMISTRY & MOLECULAR BIOLOGY	Article	96	18	10403-10408	1999	735	102.65	62.4	4.52	11.78	0.54
The ubiquitin-proteasome pathway and proteasome inhibitors	Myung, J; Kim, KB; Crews, CM	MEDICAL RESEARCH REVIEWS	PHARMACOLOGY & PHARMACY; CHEMISTRY, MEDICAL	Review	21	4	145-273	2001	303	187.5	85.96	1.92	3.52	5.36



Derwent Innovation

The world's leading patent research & analytics platform

- Assess patentability and freedom-to-operate
- Validate invention novelty
- Monitor new entrants or threats
- Analyze competitors' patent portfolios
- Investigate any litigation on an in-licensing candidate

Scan the innovation landscape with speed and confidence.

WO2005105827A2

Add to Work file | Mark record | Watch record | Download | Translate | Highlight | Print

Key summary data

Patent	Dead	Publication date	2005-11-10
DWPI family	Alive View details	Expiration date	- View factors
INPADOC family	Alive View details	Remaining life	-
Original assignee	PROTEOLIX INC., US	Domain Influence	38.29
Optimized assignee	AMGEN INC	Strategic Importance	7.49

[Jump to](#) Bibliography | Abstract | Classes/Indexing | Legal status | Family | Claims | Description | Citations | Similarity | Alerts

Bibliography

DWPI title
New compounds for enzyme inhibition, useful for treating inflammation, muscle wasting disease, cancer

Original Title
COMPOUNDS FOR ENZYME INHIBITION
COMPOSES POUR L'INHIBITION ENZYMATIQUE

English Title
COMPOUNDS FOR ENZYME INHIBITION

Assignee/Applicant
Standardized: [PROTEOLIX INC](#) [SMYTH MARK S](#) [LAIDIG GUY J](#) [BORCHARDT RONALD T](#) [BUNIN BARRY A](#) [CREWS CRAIG M](#) [MUSSEY JOHN H](#) [SCHNEEKLOTH JOHN S JR](#) [CHABALA JOHN CLIFFORD](#)

Original: PROTEOLIX INC., 225 Gateway Boulevard, South San Francisco, CA 94080, US

Abstract

DWPI abstract
(US20050245435A1)

Novelty
A compound for enzyme inhibition is new.

Detailed description
A compound having a structure of formula (I), (II), (III), or its salt, Formula (I), or Formula (II), where A=C=O, C=S, or SO₂, or optionally a covalent bond when adjacent to an occurrence of Z; L=absent or is C=O, C=S, or SO₂, preferably L is absent or C=O; M=absent or is C₁₋₁₂ alkyl; Q=absent or is O, NH, or N-C₁₋₆ alkyl; Y=absent or is O, NH, N-C₁₋₆ alkyl, S, SO, SO₂, CHOR¹⁰, or CHCO₂R¹⁰; Z=O, S, NH, and N-C₁₋₆ alkyl, or optionally a covalent bond when adjacent to an occurrence of A; R¹⁻⁴=C₁₋₆ alkyl, C₁₋₆ hydroxyalkyl, C₁₋₆ alkoxyalkyl, aryl, or C₁₋₆ aralkyl, any of which is optionally substituted with one or more of amide, amine, carboxylic acid (or its salt),




Case Activity Powered by [darts-ip](#) Part of [Clarivate](#)

WO2005105827A2 in case history
20 The patent **WO2005105827A2** appears in 20 cases.

PLAINTIFF	DEFENDANT	JURISDICTION
-	PROTEOLIX	Brazil
Onyx Therapeutics	Breckenridge Pharmaceutical	United States
Onyx Therapeutics	Cipla (+1 more party)	United States
-	Onyx Therapeutics	India
Onyx Therapeutics	Breckenridge Pharmaceutical	United States

15 more cases on Darts-ip


PROTEOLIX as plaintiff
0 No cases found



Cortellis Drug Research Advisor – Target Druggability

Game-changing interactive target ID & validation tool

- Quickly conduct target due diligence
- Verify if you have the best target
- Run a preliminary patent novelty check
- Investigate competition
- Prioritize your target




Target prioritization Complete novelty Condition novelty Early development No prioritization ⓘ

Cancer

Rank	Target		Number of related records				
	Target main name	Gene symbol	Drugs	Experimental pharmacology	Animal models	Biomarker uses	Genetic evidence
	<input checked="" type="checkbox"/> Select targets <input type="checkbox"/> Deselect		filtered (total)	filtered (total)	filtered (total)	filtered (total)	
1	<input checked="" type="checkbox"/> Ubiquitin carboxyl-terminal hydrolase BAP1	[SYN] BAP1			0 (10)	1 (336)	1 (276)
2	<input checked="" type="checkbox"/> Ubiquitin carboxyl-terminal hydrolase CYLD	[SYN] CYLD		2	0 (8)	12 (163)	9 (121)
3	<input checked="" type="checkbox"/> Hyaluronan-binding protein 2	[SYN] HABP2		37	0 (2)	0 (144)	1 (26)
4	<input checked="" type="checkbox"/> Disintegrin and metalloproteinase domain-containing protein 23	[SYN] ADAM23				0 (81)	1 (26)
5	<input checked="" type="checkbox"/> A disintegrin and metalloproteinase with thrombospondin motifs 18	[SYN] ADAMTS18				1 (72)	1 (30)
6	<input checked="" type="checkbox"/> A disintegrin and metalloproteinase with thrombospondin motifs 14	[SYN] ADAMTS14				0 (57)	1 (18)
7	<input checked="" type="checkbox"/> Calpain-5	[SYN] CAPN5	0 (1)		0 (3)	0 (62)	1 (21)
8	<input checked="" type="checkbox"/> A disintegrin and metalloproteinase with thrombospondin motifs 19	[SYN] ADAMTS19				0 (36)	1 (12)
9	<input checked="" type="checkbox"/> Ubiquitin carboxyl-terminal hydrolase 49	[SYN] USP49				0 (17)	1 (12)
10	<input checked="" type="checkbox"/> Ubiquitin carboxyl-terminal hydrolase 17-like protein 11	[SYN] USP17L11				0 (2)	1 (1)



Increase the likelihood of selecting the best-in-class or first-in-class asset.



MetaCore

Bioinformatics suite for functional analysis of OMICs data

- Visualize how your target works
- Examine genetic evidence
- Gain a molecular understanding of the disease
- Identify novel biomarkers




Accelerate biomarker discovery and make better initial go/no-go decisions on your target.

Multiple Myeloma

Table of Contents

Causal Associations (by Gene)

#	Gene	Alteration Level	Alteration Type	Alteration Subtype	Details	Abundance	Activity/Gain/Loss of Function	Normal/Pathology Concentration	Subcellular Localization Change	Organ/Tissue Distribution	Disease	Info
1	IGFBP2	DNA level	Epigenetics	Methylation	IGFBP2_HUMAN_Methylation	up				Bone Marrow	Multiple Myeloma	
2	CDKN2C	DNA level	Gene rearrangements	Large Deletion	CDKN2C_HUMAN_Deletion					Plasma Cells	Multiple Myeloma	
3	CD4	DNA level	Haplotype/SNP		CD4_HUMAN_rs2072221(C) / CD4_HUMAN_rs2072221(C)					Blood	Multiple Myeloma	
4	CDKN2A	DNA level	Epigenetics	Methylation	CDKN2A_HUMAN_Methylation	up, Indifferent	Indifferent, down			Bone Marrow Cells, Bone Marrow, Leukocytes, Mononuclear, Plasma Cells, Blood	Multiple Myeloma, Leukemia, Plasma Cell	
5	IL18	DNA level	Haplotype/SNP		IL18_HUMAN_rs1143627(C) / IL18_HUMAN_rs1143627(C)					Leukocytes, Mononuclear	Multiple Myeloma	
6	L6G3	DNA level	Haplotype/SNP		L6G3_HUMAN_rs3762725(A) / L6G3_HUMAN_rs3762725(A)					Blood	Multiple Myeloma	
7	IL18	DNA level	Haplotype/SNP		IL18_HUMAN_rs1143627(C) / IL18_HUMAN_rs1143627(C)					Leukocytes, Mononuclear	Multiple Myeloma	
8	L6G3	DNA level	Haplotype/SNP		L6G3_HUMAN_rs3762725(A) / L6G3_HUMAN_rs3762725(A)					Blood	Multiple Myeloma	
9	CYP2C8	DNA level	Haplotype/SNP		CYP2C8_HUMAN_rs1934990(C)					Blood	Multiple Myeloma	
10	IL6	DNA level	Haplotype/SNP		IL6_HUMAN_rs1800797(A)					Blood	Multiple Myeloma	



Cortellis Drug Discovery Intelligence

Comprehensive biology, chemistry & pharmacology data in one place

- Identify, prioritize and select drug candidates
- Monitor the target landscape
- Inspect competitor's activities
- Benchmark experimental performance
- Examine drug-drug interactions

Make better informed go/no-go pipeline and competitor-based decisions.

All results for "Proteasome Inhibitors"

697 Drugs & Biologics

[View results](#) [Related content](#)

97 Genes & Targets

[View results](#) [Related content](#)

108 Organic Synthesis

[View results](#) [Related content](#)

11022 Experimental Pharmacology

[View results](#) [Related content](#)

2025 Experimental Models

[View results](#) [Related content](#)

8790 Pharmacokinetics

[View results](#) [Related content](#)

0 Drug-Drug Interactions

[View results](#) [Related content](#)

6689 Clinical Studies

[View results](#) [Related content](#)

23895 Literature

[View results](#) [Related content](#)

1884 Patents

[View results](#) [Related content](#)

5283 Biomarkers 10793 Uses

[View results](#) [Related content](#)

Entry Number	Highest Phase	Code Name	Generic Name	Brand Name	Product Category	Therapeutic Group	Mechanism of Action	Organization
91537	Withdrawn - 2007	Bay-9-128 RP-9221	Aprotinin	Trasylol		Breast Cancer Therapy Hemostatics	Serine Protease Inhibitors	Bayer (Originator) National Cancer Institute (NCI)
211732	Launched - 1997	AG-1343 ARV-SR0121 LX-312857	Nelfinavir mesilate	Viracept	Radiosensitizers	Anti-Coronavirus (CoV) Drugs Anti-HIV Agents Anti-Herpes Virus Drugs Cervical Cancer Therapy	HIV-1 Protease Inhibitors Proteasome Inhibitors Viral Fusion Inhibitors	Agouron (Originator) Japan Tobacco (JT) Japan Tobacco (Japan Tobacco (JT)) Maastricht Radiation Oncology (MAASTRO)
199183	Launched - 1996	L-735524 MK-639	Indinavir sulfate	Crixivan		Anti-HIV Agents Kaposi's Sarcoma Therapy	HIV Protease Inhibitors	Istituto Superiore di Santa MSD KK (Originator) Merck & Co. (Originator)

Drug-Drug Interactions


Prescription

0	0	0	8	14	0
Contraindicated	Not Recommended	Warning/Precaution	No Interaction	Beneficial	Undisclosed

Apply Filters | Sorted by relevance | Expand all

Showing 1-20 of 22 Drug-Drug Interactions records for "Carfilzomib"

Evaluated Entity	Interacting Entity	Interaction Type	Outcome	Prescription	Population / Study Model
Dexamethasone	Carfilzomib	Pharmacokinetics (ADME)	No Interaction	No Interaction	Humans
Carfilzomib	Dexamethasone	Pharmacokinetics (ADME)	No Interaction	No Interaction	Humans
Lenalidomide	Carfilzomib	Pharmacodynamics	Pharmacodynamics	Beneficial	Humans/Adult/Multiple myeloma
Lenalidomide	Carfilzomib	Pharmacodynamics	Pharmacodynamics	Beneficial	Humans/Asian/Adult/Multiple myeloma
Selinexor	Carfilzomib	Pharmacodynamics	Pharmacodynamics	Beneficial	Mice/Multiple myeloma:Severe combined immunodeficiency disease (SCID)



Cortellis CDDI – Biomarkers

Broadest coverage of biomarker uses at every stage of Drug R&D

- Identify biomarkers to stratify your patients
- Better understand disease pathology
- Examine a biomarker's uses and level of validity
- Classify biomarkers into lifecycle phases

Biomarkers "Protease Inhibitors" x [refresh] [search] [settings]

Biomarkers **Biomarker Uses** Biomarker Kits

Apply Filters Sorted by relevance Showing 1-20 of 8544 Biomarker Uses records for "Protease Inhibitors"

Biomarker Uses - C... (620) x

<input type="checkbox"/>	Biomarker Name	Indication	Population	Role	Highest Validity	Drugs	Supporting	Supporting / Conflicting	Conflicting	
<input type="checkbox"/>	Alanine transaminase	Sepsis, severe	Adult	Monitoring Treatment Efficacy	Late Studies in Humans	1	1	0	0	View Use
<input type="checkbox"/>	Creatine Kinase, MB Form	Systemic inflammatory response syndrome	Cardiovascular Disorders	Monitoring Treatment Efficacy	Late Studies in Humans	1	1	0	0	View Use
<input type="checkbox"/>	Antithrombin III- protease complex	Occlusion, arterial coronary	High Risk	Monitoring Treatment Efficacy	Late Studies in Humans	1	1	0	0	View Use
<input type="checkbox"/>	Hemoglobin	Occlusion, arterial coronary	High Risk	Monitoring Treatment Efficacy	Late Studies in Humans	1	1	0	0	View Use
<input type="checkbox"/>	Lactic Acid	Sepsis, severe	Adult	Monitoring Treatment Efficacy	Late Studies in Humans	1	1	0	0	View Use

Biomarker Use Record Biomarker Kits


General Information

Biomarker Name	Caspase-3	Role	Monitoring Treatment Efficacy
Indication Type	Condition	Highest Validity	Early Studies in Humans
Indication	Multiple myeloma	Population	All

Techniques & Substrates

Technique	Substrate	Validity	Drugs	Genetic Variants	Supporting	Supporting/Conflicting	Conflicting
Not specified	Not specified	Experimental	4	0	3	0	0
Spectrophotometry	Cell lysates	Experimental	2	0	1	1	0
High Throughput Nucleotide Sequencing	DNA	Early Studies in Humans	0	0	0	0	1
Real Time PCR	mRNA	Experimental	1	0	1	0	0
Immunofluorescence	Cell lysates	Experimental	1	0	1	0	0

Increase your probability of success in clinical trials, and accelerate drug development.



OFF-X

The largest translational safety & toxicity intelligence portal

- Anticipate toxicity & safety events
- Examine the safety profile of in-licensing candidates
- Investigate the toxicity of competing treatments
- Differentiate your asset
- Monitor regulatory concerns and liabilities

Design better and safer protocols which mitigate unintended risks to patients.

ADVERSE EVENT | SYSTEM ORGAN CLASS | TARGET NAME: 20-S PROTEASOME

Show 100 entries

ADVERSE EVENT / SOC	COMPARATIVE GLOBAL ADVERSE EVENT TRANSLATABILITY	BIOLOGICAL ROLE & PRECLINICAL PHARMACOLOGICAL EVIDENCE				CLINICAL PHARMACOLOGICAL EVIDENCE					
		TARGET EXPRESSION (Source: Human Protein Atlas)	HUMAN GENETIC VARIANTS	KNOCKOUT / KNOCKDOWN ANIMAL DATA	IN VITRO DATA / PATIENTS SAMPLE	PRECLINICAL	PHASE I	PHASE II	PHASE III	CLINICAL REGULATORY	POST-MARKETING
All Adverse Events	817	0	0	38	184	308	405	228	1255	499	567
Death (General disorders and admi...)				1	7	3	3	3	11	13	5
Neurotoxicity (Nervous system disorders)				5	6				1	7	4
Neuropathy peripheral (Nervous system disorders)				1	6	8	9	12	23	45	5
Cardiotoxicity (Cardiac disorders)								3	4	7	9


20-S Proteasome Inhibitors

ADVERSE EVENT | SYSTEM ORGAN CLASS

Show 50 entries

Heatmap based on OFF-X Drug Score
 Very High Evidence (Red) | Medium Evidence (Yellow) | Low Evidence (Green) | Not Associated (Grey) | Target/Class Evidence Only


ADVERSE EVENT	SYSTEM ORGAN CLASS	ALERT TYPE		ALERT PHASE							
		CLASS ALERT	DRUG ALERT	BORTEZOMIB LAUNCHED (2009)	CARFILZOMIB LAUNCHED (2012)	DELANZOMIB LAUNCHED (2015)	IXAZOMIB LAUNCHED (2015)	LACTACISTIN	MARIZOMIB PHASE III	MLN273	OPROZOMIB PHASE I/II
All Adverse Events	All System Organ Classes	44	3271	1568	1180	13	471	1	135	4	36
Neuropathy peripheral	Nervous system disorders	4	106	High	High	High	High	Low	Low	Low	Low
Thrombocytopenia	Blood and lymphatic system disorders	0	98	High	High	High	High	Low	Low	Low	Low
Diarrhoea	Gastrointestinal disorders	0	79	High	High	High	High	Low	Low	Low	Low
Nausea	Gastrointestinal disorders	0	79	High	High	High	High	Low	Low	Low	Low
Fatigue	General disorders and administration site ...	0	73	High	High	High	High	Low	Low	Low	Low
Anaemia	Blood and lymphatic system disorders	0	59	High	High	High	High	Low	Low	Low	Low



DRUG NAME: CARFILZOMIB

Show 50 entries

OFF-X DRUG SCORE	ADVERSE EVENT	SYSTEM ORGAN CLASS	ALERT TYPE		ALERT PHASE			NUMBER OF ALERTS	LABEL REFERENCE	
			CLASS ALERT	DRUG ALERT	TARGET DISCOVERY / PRECLINICAL	CLINICAL / POST MARKETING	FDA		EMA	
All Adverse Events	302	All System Organ Classes	23	55	1144	79	1117	1196		
Very High Evidence	Anaemia	Blood and lymphatic system dis...	0	26	26	0	26	26	L	L
Very High Evidence	Cardiac failure	Cardiac disorders	3	43	43	3	43	46	L	L
Very High Evidence	Cardiotoxicity	Cardiac disorders	8	19	19	5	22	27	L	L
Very High Evidence	Death	General disorders and administr...	1	22	22	3	20	23	L	L
Very High Evidence	Dyspnoea	Respiratory, thoracic and media...	0	26	26	0	26	26	L	L





PHASE 2 MARKET ASSESSMENT

Competitive Intelligence

The trusted and industry-leading drug pipeline database

- Efficiently track the competitive landscape
- Understand competitors' product positioning
- Differentiate your asset
- Assess expected product performance
- Determine potential market share
- Examine safety findings

Confidently make critical product, portfolio and competitor-based decisions.



Anticancer proteasome inhibitors

Strengths

- Novel second-generation irreversible proteasome inhibitor; induces apoptosis and cell cycle arrest in multiple myeloma (MM) cells resistant to Velcade [1235208]
- Equal potency to Velcade, but lower incidence of neurotoxicity and neutropenia, possibly due to greater selectivity for the chymotrypsin-like protease and lack of off-target activity resulting from less cross-reactivity at the trypsin and caspase-like proteases in the 26S proteasome [1235212], [1235213]
- Good efficacy in the salvage setting; in phase II studies for relapsed and/or refractory MM, single-agent Kyprolis resulted in an overall response rate (ORR) of 24% and overall survival of 15.6 months; ORR for Velcade-naïve patients was 53% [1198101], [1192926], [1062444]
- Also approved for use in combination with Revlimid and dexamethasone in relapsed MM, based on ASPRE data which showed a progression-free survival (PFS) of 29 months, an unprecedented PFS benefit in second-line treatment; safety was also confirmed, vindicating the drug from previous concerns of potential cardiac, renal and pulmonary toxicities [1680749]
- ENDEAVOR showed an impressive 50% reduction in risk of disease progression for Kyprolis plus dexamethasone compared with Velcade plus dexamethasone (median PFS of 18.7 versus 9.4 months, median duration of response of 21.3 versus 10.4 months, and median overall survival of 47.8 versus 38.8 months, respectively) in patients with relapsed MM [1637451], [1664217], [1357083]

Weaknesses


- Only approved in relapsed MM [1310245]
- The phase III CLARION trial in frontline MM missed its primary endpoint of superiority over Velcade in PFS (22.3 versus 22.1 months) [1799376]
- The FOCUS trial testing Kyprolis versus best supportive care in relapsed/refractory MM did not achieve its primary endpoint of improving median overall survival (10.2 and 10.0 months, respectively) [1655346], [1596111]
- Safety concern of cardiac toxicity; the label notes 6 and 8% rates of cardiac failure reported in two trials. Also of renal and pulmonary toxicity (renal insufficiency, including renal failure, in 10% and dyspnea in 28% of patients) [1310245]
- Label also warns of pulmonary hypertension, tumor lysis syndrome, hepatic toxicity and failure, and venous thrombosis and hemorrhage [1310245]
- The most common adverse events reported in at least 20% of patients include anemia, fatigue, thrombocytopenia, dyspnea, diarrhea and cough [1310245]
- Inconvenience of frequent intravenous dosing (2 consecutive days each week for 3 weeks, followed by 12 days rest period) [1310245]
- Development in other indications, including chronic lymphocytic leukemia and small-cell lung cancer, has presumably been [1310245]

Opportunities

- Disease burden; MM is the second most common hematological cancer, affecting approximately 230,000 people worldwide, with an estimated 114,000 new cases diagnosed annually. Also increasing prevalence of MM due to better diagnosis and improved patient survival [1676798], [1396970]
- Around 70% of patients with active MM are not eligible for stem cell transplantation due to age or other health conditions and will be reliant on drug-based therapies. The majority of patients with MM relapse and require additional therapy [1173690], [1396970]

Threats

- Pomalyst, which was approved in the salvage setting in February 2013 and has compelling response rates [1368875], [1268895]
- Competition from entrenched market leaders Velcade and Revlimid, although these are usually used more in the front-line setting, as well as other established drugs including thalidomide; peripheral neuropathy is a more limited concern with the subcutaneous version of Velcade which may negate Kyprolis's toxicity advantage [1172398], [1235430], [1310245], [1572624]
- Generic entry in Europe of market leader Velcade in 2015 could also



Deals Intelligence

The gold standard biopharma deals database

- Quickly examine deal valuations & financial terms
- Easily benchmark funding, licensing, and M&A deals
- Analyze potential partners' deal history
- Inform deal negotiations
- Easily visualize deal trends & deal predictions (Q2 2021)

Make confident buy or build decisions and strike your best possible deal.

Onyx acquires Proteolix

Snapshot | Highlight | Search Terms & Synonyms | < Previous | Next >

Drugs: EVENTS

Patents: SUMMARY

Contract: In October 2009, Onyx Pharmaceuticals announced that it is acquiring the proteasome inhibitor Proteolix. The acquisition was completed on November 16, 2009. In January 2011, the parties entered into a license agreement for the development and commercialization of a novel proteasome inhibitor. The license agreement was replaced by a new license agreement in January 2011.

Events

Summary

Timeline

Date	Event Type	Description
20-Jul-2012	Other Deal Update	- In July 2012, Kyprolis (carfilzomib) received FDA approval. \$170M of the total contingent acquisition was attributable to this milestone.
27-Jan-2011	Deal Amendment	- In January 2011, the parties entered into a license agreement for the development and commercialization of a novel proteasome inhibitor. The license agreement was replaced by a new license agreement in January 2011.
16-Nov-2009	Deal Completed	- On November 16, 2009, the acquisition of Proteolix by Onyx Pharmaceuticals was completed.

Amgen acquires Onyx Pharmaceuticals

Snapshot | Highlight | Search Terms & Synonyms | < Previous | Next >

Drugs: EVENTS

Patents: SUMMARY


Contract: In June 2013, Amgen made an unsolicited offer to acquire Onyx Pharmaceuticals. The offer was accepted by the board of directors of Onyx Pharmaceuticals on August 28, 2013. The acquisition was completed on September 18, 2013. The acquisition was valued at approximately \$9.7 billion net of estimated Onyx cash. The acquisition was completed on September 18, 2013.

Events

Summary


Timeline

Date	Event Type	Description	Drug(s)	Stage	Payment Type	Value (USD m)
01-Oct-2013	Deal Completed	- On October 1, 2013 Amgen completed the acquisition of Onyx Pharmaceuticals for \$125/share in cash, valued at \$9.7 billion net of estimated Onyx cash [1483015].			Upfront Payment to Principal Company;	=9,700.00
18-Sep-2013	Other Deal Update	- In September 2013, the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, was terminated early on September 18, 2013 which was scheduled to expire on September 23, 2013 [1478623].				
	Other Deal Update	- In August 2013, Amgen would acquire all of the outstanding shares of Onyx for \$125/sh in cash, valued at \$10.4 billion, or \$9.7 billion net of estimated Onyx cash [1469238].				
	Original Deal	- In June 2013, Amgen made an unsolicited offer to acquire Onyx Pharmaceuticals for \$120/share in cash, a 38% premium to Onyx' closing price on June 28, 2013 valued at approximately \$8.76 billion. - Onyx Pharmaceuticals develops and commercializes therapies for cancer and the main products would include: - Nexavar (sorafenib tosylate) co-developed and co-marketed with Bayer for kidney cancer (advanced renal cell carcinoma) and advanced primary liver cancer (hepatocellular carcinoma). (See 4/1994 transaction). - Kyprolis (carfilzomib) approved for multiple myeloma and solid tumors.		Registered		



Data

Drugs Highest Status (Deal Start)	Deal Counts	Deal Size Counts (Total Projected Current)	Deal Size Sum (Total Projected Current)	Deal Size Average	Deal Size Max	Deal Size Min	Upfront Payment Count	Upfront Sum (USD M)	Upfront Average
Launched	12	12	34024.65	2835.39	11400	4.25	8	23727.08	2965.89
Registered	6	6	17210.5	2868.42	8800	35.5	6	16759.7	2793.28
Pre-registration	1	1	0.56	0.56	0.56	0.56	1	0.56	0.56
Phase 3 Clinical	18	18	6887.3	382.63	1275	0.47	13	1617.87	124.45
Phase 2 Clinical	27	27	21275.63	787.99	10434	0.69	20	3730.9	186.55
Phase 1 Clinical	8	8	4078.46	509.81	1878	0.65	7	144.1	20.59
Preclinical	20	20	15126.27	756.31	5046	0.7	13	339.55	26.12
Discovery	17	17	10022.36	589.55	3665.5	4.87	13	867.83	66.76
	3	3	1535.5	511.83	1080	1.5	1	0.5	0.50
Grand Total	112	112	110161.23	983.58	11400	0.47	82	47188.09	575.46



PHASE 3 CLINICAL TESTING

Cortellis Clinical Trials Intelligence

Insights into the landscape of ongoing clinical trials

- Evaluate the design of precedent studies
- Benchmark patient enrollment and timelines
- Define the right endpoints and select biomarkers
- Pinpoint adverse events
- Monitor competing trials
- Search for experienced sites
- Prioritize sites by performance, availability and competition

13733 Clinical Trial results with filter(s) applied: Coronavirus disease 19 Infection

Report Type: Clinical Trials (483380)

Search within Results: [Search]

Condition: Coronavirus disease 19 Infection (13733)

Patient Segment: A Clinical Study of Nasya and Rasayan In Post COVID-19

Title	Condition	Patient Segment	Biomarkers	Interventions	Phase
Effect of ventilatory changes in patients recovering from recent COVID infections, who are receiving general anesthesia	Coronavirus disease 19 Infection; General anesthesia		Arterial oxygen saturation ; Plateau pressure ; Six-minute walk distance	general anesthesia alone	Phase Not Applicable
Immunogenicity and safety of heterologous booster vaccination with the covid-19 recombinant vaccine (AstraZeneca/Fiocruz) , covid-19 mRNA vaccine (Pfizer/Wyeth) or covid-19 recombinant vaccine	Coronavirus disease 19 Infection			AZD-1222 alone; CoronaVac alone; Janssen COVID-19 Vaccine alone; tozinameran alone	Phase 4 Clinical
A Clinical Study of Nasya and Rasayan In Post COVID-19	Coronavirus disease 19 Infection			Variable regimens including Ashwagandha Kshirpaak and Guduchi GhanaVati , Pachana , Shodhana Nasya	Phase 2 Clinical

Site Name	City	State / Province / County	Postal Code	Country / Territory	Total Trial Count	Matched Trial Count	Top Therapy Areas
University Hospital for Tumors Ambulance	Zagreb	Grad Zagreb	10000	Croatia	276	33	Cancer; Gastrointestinal; Neurology/Psychiatric;
Sisters of Charity Hospital	Zagreb	Grad Zagreb	10000	Croatia	80	13	Cancer; Neurology/Psychiat
Clinical Hospital Dubrava	Dubrava	Zagrebacka	10000	Croatia			
Clinical Hospital Center Rijeka	Rijeka	Primorsko-Goranska	51000	Croatia			
KBC Split	Split	Splitsko-Dalmatinska	21000	Croatia			
Zadar General Hospital	Zadar	Zadarska	23000	Croatia			
Special Hospital for Medical Rehabilitation	Krapinske Toplice	Krapinsko-Zagorska	49217	Croatia			
Merkur Clinical Hospital	Zagreb	Grad Zagreb	10000	Croatia			
Sveti Duh	Zagreb	Grad Zagreb	10000	Croatia			
General Hospital Karlovac							

University Hospital for Tumors Ambulance

Zagreb Grad Zagreb Croatia 10000

Matched Condition: Cardiovascular disease

Top Therapy Areas: Cancer, Gastrointestinal, Neurology/Psychiatric

Top Sponsors: Roche Holding AG, F Hoffmann-La Roche AG, AbbVie Inc

Total Trials	Matched Trials	Ongoing Trials
276	33	74

Site Statistics

10 Ongoing Matched Trials	0 Completed Total Trials in past 12 months	0 Completed Matched Trials in past 12 months
---------------------------	--	--

400K+
Global clinical trials

2900+
Diseases and therapeutic areas

200K+
Clinical sites across 200+ countries



39
Trial registries

Cortellis Clinical Trials Intelligence

Insight on global trial sites


- Search for experienced sites
- Prioritize sites by performance, availability and competition
- Validate CRO input
- Uncover high level incidence and prevalence
- Identify experienced investigators (2022)

Position your clinical trials for greater success by selecting the best sites.



Summary

Unprecedented value from an end-to-end lifecycle perspective that empowers more proactive and better-informed decisions with speed and confidence.



Every product we use, medical treatment we receive and service we consume has been imagined, created and improved in a continuous, connected cycle of innovation.

Clarivate operates at the heart of that lifecycle. We give our customers the lens of clarity—the insights they need to turn bold ideas into life-changing innovations



Appendices




Data Citation Index

The Data Citation Index makes it easy to bring research data into your workflow.



Researchers

- **Save time** spent looking for data by searching across content from **over 430** repositories in one place.
- **Track citations to the data and software you have deposited.**
- **10.4 million total items indexed**
- Provides data studies from **1900-present**



Librarians

- **Promote the value and importance of sharing data** & following the best data management practices.
- **Provide a trusted reference** for faculty unsure of where to deposit data.

[Master Repository List](#)



Genome Portal

DRUGBANK



PANGAEA.

Data Publisher for Earth & Environmental Science






ADA AUSTRALIAN DATA ARCHIVE

Drug Timeline & Success Rates

First-to-market machine learning-based predictive analytics tool

- Confidently make critical portfolio decisions
- Monitor competitors' success rates & timelines
- Gain a reliable 3rd party validation
- Inform portfolio planning & prioritization.



Drug name	Time to Registration (Years)	Probability of Success
marizomib (iv, cancer), Triphase/Celgene Glioma US	3.4	54%
marizomib (iv, cancer), Triphase/Celgene Multiple myeloma US	3.5	58%
marizomib (iv, cancer), Triphase/Celgene Glioblastoma US	3.6	22%
marizomib (iv, cancer), Triphase/Celgene Glioblastoma Europe	3.8	40%

Yield smarter portfolio planning and R&D investment decisions for long term success.




Table of contents [Expand all](#)

Search within Content

GEOGRAPHIES

US Trend Tracking

Healthcare Facility Targeting

US Market Forecast Updates

Canada Market Forecast Updates

Europe Market Forecast Updates

Europe Impact Assessment Summary

Aesthetics

COVID-19 Market Impact Forecast Methodology

DISPLAY **All** 3 0 0

Last updated 29 January 2021

Determining and forecasting the impact on medtech markets

MARKET IMPACT OF COVID-19: MEDTECH 360 FORECAST METHODOLOGY / DECISION RESOURCES GROUP


COVID-19: Determining and forecasting the impact on medtech markets

The forecast within each Medtech 360 market analysis was created using these primary modeling components:

COVID-19 Impact Forecast: Primary Modeling Components

 Determining initial procedure deferral during the time of peak pandemic impact

 Estimating the proportion of deferred procedures that will be recovered after the impact peak



COVID-19 Impact Assessment Summary, by Therapy Area, Europe

Factor	Aesthetics	Cardiovascular	Dental	Endoscopy and Open Surgery	Gynecology	Imaging	Orthopedics
Procedure Volumes	Strong	Moderate	Strong	Strong	Moderate	Moderate	Moderate
ASP:s	Strong	Weak	Moderate	Weak	Weak	Moderate	Weak
New Product Launches	Moderate	Moderate	Moderate	Moderate	Weak	Weak	Strong
Clinical Trials	Moderate	Strong	Moderate	Moderate	Moderate	—	Moderate
Supply Chain	Weak	Moderate	Weak	Moderate	Moderate	Moderate	Moderate

Decision Resource Group (DRG)

Find out what impact Covid-19 is having on the medtech/pharma markets.

See today's BioWorld

Novavax's COVID-19 vaccine shows 100% protection against severe disease

By Lee Landenberger March 12, 2021



Data from two [Novavax Inc.](#) clinical trials show its COVID-19 vaccine had 100% protection against severe disease, including hospitalization and death, paving the way for an emergency use authorization submission in the U.S.

Mild and moderate COVID-19 was dramatically reduced in both studies, according to the data, and some efficacy was confirmed in variant strains.

Final efficacy numbers from Novavax's phase III study of [NVX-CoV2373](#) revealed the vaccine was 96.4% effective against mild, moderate and severe disease caused by the original COVID-19 strain. The efficacy numbers are very close to those



Credit: Novavax Inc.

BioWorld

With writers and editors around the globe, BioWorld reports the breaking news. Providing key perspectives on: medicines; companies; business transactions; and regulatory information.

Discovery & Translational Science (DTS) Consulting, Data & Insights

Accelerate your research with advanced analytics and actionable insights

Deep domain knowledge and advanced data science capabilities

Innovation Monitoring

- Predict an emerging technology that has the potential to be the next blockbuster
- ❑ **RWD-based KOL Identification**
 - Find the top thought leaders to uncover unmet medical needs and emerging research areas

Target Identification / Biomarker Discovery

- Identify and systematically prioritize targets and biomarkers for higher chances of drug development success.
- ❑ **Patient Stratification**
 - Classify patient subgroups by drug response & resistance

Computational Biology Methods for Drug Discovery (CBDD)

- Discover novel approaches to network and pathway analysis through collaboration with industry leaders & Innovators

Indication Prioritization

- Systematically find the most meaningful indications for a given target of interest

Mechanism Reconstruction


- Reconstruct biological mechanisms from OMICs data

Toxicity Prediction

- Understand the potential safety risk and rank-order your lead compounds relative to potential toxicity

Drug Repurposing

- Find other disease areas for your existing product to extend revenues and patent life



Consulting Services for Clinical Development

Transform and accelerate your clinical trials

Deep domain knowledge and hands-on industry expertise

RWD-based Integrated Patient Journey

- Understand drug performance in the real world in contrast to clinical setting through real world data
- Uncover where in the patient journey the therapy can be introduced to address the unmet medical need or patient pain points
- Identify adverse events experienced by the patients and what the clinical and economic impacts are from those
- Pinpoint influence levers to inform commercial and patient engagement strategies

Intelligent Trials: Study & Site Optimization


- Optimize your study design, pick the best performing sites, and accurately size and locate your target populations

Pricing & Reimbursement

- Inform clinical development strategy and avoid costly amendments by understanding the current value-based pricing and contracting strategies and activities

Health Economics Outcomes Research (HEOR)

- Avoid costly protocol amendments by incorporating economic endpoints into the trial design for evidence of the product's economic value for reimbursement decisions
- Conduct an evidence gap analysis and develop patient outcomes assessments for successful market access



Consulting Services for Clinical Operations

Optimize your clinical performance

Deep domain knowledge and hands-on industry expertise

RWD-based KOL Identification


- Discover and profile the best thought leaders in your disease area to consult with
- Segment physicians based on location, disease area, patients treated, procedures performed, hospital or care facility affiliations as well as their referrals

RWD-based Patient Finder

- Identify hospitals or practices that have the highest patient groups of interest, and physicians that manage patient groups within the trial inclusion criteria
- Influence physicians to enroll patients into your clinical study

Center for Medicines Research (CMR) International

- Benchmark clinical performance of peers to optimize operations and cycle times
- Inform feasibility analysis and clinical strategy by leveraging country, study, and site level performance data



Additional Resources

Web of Science Mobile App - My Research Assistant "MyRA" brings the Power of WoS to the Palm of your Hand

Create an account and log in using Clarivate One Account.

Share articles via other apps on your device

Dive into the citation network with cited, citing, and related articles, and direct links to author, research area, journal, and funder searches

News feeds as your home screen, alerting you to the latest articles you are interested in.

Search Web of Science using basic and advanced search capabilities

Save articles to your reading list for later viewing

Read the full text article on the publisher website within the app.

Background text: Social collaboration networks, Open access content, Personalized researcher app, 2M+ active profiles, Grant review, Unique author ID, Peer review network, Research impact, Data citation, 30% even more, -gen web of science

[Apple download](#)
[Google Play download](#)
[Learn more](#)

Additional resources

[Web of Science Learning](#) >

[Web of Science Academy](#) >

[Events & Webinars](#) >

[LibGuides](#) >

[Videos](#) >

[Web of Science Blog](#) >

[Web of Science news hub](#) >

[Researcher Recognition](#) >

[Cortellis information](#)



Customer Service - Available 24x5

support.clarivate.com/ScientificandAcademicResearch



LIVE CHAT

Click [here](#) to reach a WoS agent



PHONE

Dial +44 8003288044



EMAIL or WEBFORM

WoSG.support@clarivate.com or click [here](#) to send us a Webform



KNOWLEDGE BASE

Click [here](#) to visit our extensive Knowledge Base


Links to popular articles include: [Remote Access to WoS](#), [h-index Information](#)

Resources for teaching and learning

Stay up to date on product developments, and provide on-demand support for students and faculty

Web of Science Learning Page


Point students and faculty to “how to” content available 24/7.



[Learning Page](#)

LibGuides

Save time updating your LibGuides by reusing pages from ours.



clarivate.libguides.com/home

Librarian Toolkit


Quick links to individual databases, factsheets, and more.



[View Toolkit](#)

Web of Science Academy

Online training supporting academics in conducting research with integrity



[Join our Web of Science Academy](#)



Köszönöm!

